Literature DB >> 16446321

Angiogenesis inhibitors and hypertension: an emerging issue.

Domenic A Sica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16446321     DOI： 10.1200/JCO.2005.04.5740

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  37 in total

1.  Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Authors:  George D Demetri; Christopher R Garrett; Patrick Schöffski; Manisha H Shah; Jaap Verweij; Serge Leyvraz; Herbert I Hurwitz; Antonio Lopez Pousa; Axel Le Cesne; David Goldstein; Luis Paz-Ares; Jean-Yves Blay; Grant A McArthur; Qiang Casey Xu; Xin Huang; Charles S Harmon; Vanessa Tassell; Darrel P Cohen; Paolo G Casali
Journal:  Clin Cancer Res       Date:  2012-06-01       Impact factor: 12.531

Review 2.  Chemotherapy agents and hypertension: a focus on angiogenesis blockade.

Authors:  Manish Jain; Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

Review 3.  Impact of concomitant medications on obstructive sleep apnoea.

Authors:  Ingrid Jullian-Desayes; Bruno Revol; Elisa Chareyre; Philippe Camus; Céline Villier; Jean-Christian Borel; Jean-Louis Pepin; Marie Joyeux-Faure
Journal:  Br J Clin Pharmacol       Date:  2016-11-24       Impact factor: 4.335

Review 4.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

Review 5.  Non-interventional management of resistant hypertension.

Authors:  Michael Doumas; Costas Tsioufis; Charles Faselis; Antonios Lazaridis; Haris Grassos; Vasilios Papademetriou
Journal:  World J Cardiol       Date:  2014-10-26

6.  Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Authors:  Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 8.  Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Ai-Na He; Zan Shen; Yang Yao
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

9.  Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.

Authors:  Anita Schwandt; Laura S Wood; Brian Rini; Robert Dreicer
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 10.  Resistant Hypertension Updated Guidelines.

Authors:  Irene Chernova; Namrata Krishnan
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.